You asked a good question that I’ve wondered as well. Basically someone has to show that immunity to one variant confers immunity to another, which is not at all obvious since presumably they have different epitopes. I guess what people are suggesting is that the epitopes are distinct enough that a targeted vaccine might not cover both, but not so distinct that they behave like separate infections in vivo. But I would hope that an expert can chime in and shed some light here.